KSE - Delayed Quote KRW

Shinpoong Pharmaceutical Co.,Ltd (019170.KS)

13,640.00 +280.00 (+2.10%)
At close: April 26 at 3:30 PM GMT+9

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
NameTitlePayExercisedYear Born
Mr. Chang-Kyun Kim President -- -- 1956

Shinpoong Pharmaceutical Co.,Ltd

161, Yeoksam-ro
Gangnam-gu
Seoul, 06246
South Korea
82 2 2189 3400 https://shinpoong.co.kr
Sector: 
Healthcare

Description

Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products. In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.

Corporate Governance

Shinpoong Pharmaceutical Co.,Ltd’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 10; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Dec 29, 2020
    Ex-Dividend Date

Upcoming Events

May 13, 2024 - May 17, 2024
Shinpoong Pharmaceutical Co.,Ltd Earnings Call